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Abstract
© 2018, Bionika Media Ltd. All rights reserved. Objective. To evaluate the medicinal properties
of an agent containing ethinylestradiol (EE) and chlormadinone acetate (CMA) in contraceptive-
needing patients within the framework of the pharmacological epidemiological observational
project. Subjects and methods. The investigation enrolled 161 contraception-needing patients.
All the patients had no contraindications to combined oral contraceptives (COCs) and conditions
in which COCs should be used with caution. All the women took EE in combination with CMA in a
21/7 cyclic regimen for contraception. To evaluate the medicinal properties of the agent, the
investigators  studied  its  effects  on  the  nature  of  menstruation  and  related  symptoms
(tenderness, frequency of breast pain prior to menstruation, abundant discharge), and the skin
(acne frequency  and severity,  skin  oiliness).  Results.  During  the  investigation,  there  were
pronounced changes associated with a decrease in complaints related to painful menstruation,
their abundance, premenstrual breast pain; acne severity and higher skin fat content reduced.
Conclusion. The findings may consider COC with EE/CMA as an agent having an anti-androgenic
effect that can reduce the frequency and degree of manifestation of acne, have a positive effect
on the nature of menstruation.
http://dx.doi.org/10.18565/aig.2018.3.109-115
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